D05.80

Clinical Causes: Genetic factors which may predispose individuals to abnormal cell growth in breast tissue. Hormonal influences, especially prolonged exposure to estrogen without adequate protective factors. Environmental exposures that may influence cellular mutations in breast tissue. History of benign breast disease or previous biopsies that indicate abnormal cellular changes. Age-related changes in breast tissue, often increasing the risk with advancing years.

Key Symptoms: Usually no noticeable symptoms; often detected during routine screening or imaging tests. Presence of a non-painful lump or abnormal area found through mammography. Alterations in breast shape or size, though these are less common in in situ conditions. Possible nipple discharge if the abnormality affects the ducts extensively. Changes in skin appearance over the breast, such as redness or dimpling, which are rare in early stages.

Diagnosis Path: Mammography: The primary screening tool that can detect abnormal calcifications or masses suggestive of in situ carcinoma. Breast ultrasound: Used to evaluate the nature of a detected lump or abnormal area. Magnetic Resonance Imaging (MRI): May provide detailed images for further assessment, especially in dense breast tissue. Biopsy: The definitive method involving removal of a tissue sample for microscopic examination to confirm carcinoma in situ and its specific type.

Treatment Protocols: Surgical excision: Removing the abnormal cells, often via a lumpectomy or wide local excision, to eliminate the lesion. Radiation therapy: Often recommended after surgery to reduce the risk of recurrence in the same area. Hormonal therapy: For certain types that are hormone receptor-positive, treatments like tamoxifen may be considered. Regular follow-up: Ongoing monitoring through imaging and clinical exams to detect any changes early. Potential participation in clinical trials: Access to emerging therapies or investigational treatments.